Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 21, 2019
Pharmacy Choice - News - U.S. Pharmaceutical Industry - February 21, 2019

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/21/19 - 75 Biggest Movers From Yesterday
Gainers Kandi Technologies Group Inc shares gained 34.34 percent to close at $7.98 on Wednesday after the company reported NHTSA approval of 2 electric vehicle models. Arca Biopharma Inc shares surged 31.27 percent to close at $0.5080 on Wednesday after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support a
2/21/19 - Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by HC Wainwright with a $30.00 price target
Analyst Ratings For Abeona Therapeutics Inc (NASDAQ:ABEO) Today, HC Wainwright reiterated its Buy rating on Abeona Therapeutics Inc (NASDAQ:ABEO) with a price target of $30.00. There are 8 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock. The current consensus rating on Abeona Therapeutics Inc (NASDAQ:ABEO) is Buy w
2/21/19 - ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 8 th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m....
2/21/19 - Acasti Pharma Recognized in TSX Venture Exchange's 2019 Venture 50
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, announces it has been recognized by the TSX Venture Exchange in its 2019 Venture 50, a ranking of the strongest companies on TSX Venture Ex
2/21/19 - Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences [T-break Tech (Middle East)]
-Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the Company will be presenting at the following investor conferences:. 8th Annual Leerink Global Healthcare Conference on February 27th, 2019 at...
2/21/19 - Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 CARE study of plazomicin in a Letter to the Editor. Achaogen's EPIC...
2/21/19 - Achaogen Announces ZEMDRI (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 EPIC study of ZEMDRI. Wagenlehner, M.D., Director, Clinic for Urology,
2/21/19 - Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation
SEATTLE- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is the first in Achieve's ORCA Program, which aims to evaluate the effectivenes
2/21/19 - Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated diseases, today announced the expansion into a second office located at 1777 Sentry Parkway West in Blue Bell, Pa. The approximately 12,000 square-feet office space will serve as.
2/21/19 - Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic
SAN DIEGO- Adamis Pharmaceuticals Corporation announced today that the article entitled' Higher doses of naloxone are needed in the synthetic opioid era' has been published in the peer reviewed journal Substance Abuse Treatment, Prevention, and Policy. According to statistics published by the Centers for Disease Control and Prevention in 2017, drug
2/21/19 - Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial's AD04 for its Phase 3 Trial
This partnership brings together critical capabilities to allow the commencement of Adial's planned initial Phase 3 trial, with Catalent providing packaging and distribution. Catalent has a robust, global network, with the presence in Europe and the U.S. to provide flexible, integrated clinical supply services for investigational medicinal products
2/21/19 - Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced the pricing of an underwritten public offering of 2,475,000 shares of its common stock and warrants to purchase up to 1,856,250 shares of the Company's common stock. Maxim Group LLC is acting as the book-r
2/21/19 - Advanced Parenteral Drug Delivery Devices Market: Global Industry Analysis and Opportunity and Forecast 2019 To 2024
WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024" reports to its database. WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to
2/21/19 - Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights.
2/21/19 - Alcoholics may benefit from multimillion-dollar grant for opioid-blocking implant, says Anaheim company [The Orange County Register]
BioCorRX, a small Anaheim company, believes it can help break this vicious cycle, and the National Institute on Drug Abuse is inclined to agree. The institute part of the National Institutes of Health has awarded BioCorRX a grant to help develop a naltrexone implant to treat what is officially called "opioid use disorder." BioCorRx in Anaheim,
2/21/19 - Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019/ PRNewswire/ Amgen, Cytokinetics, Incorporated and Servier today announced that METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potenti
2/21/19 - ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
WESTMINSTER- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design of a pivotal Phase 3 clinical..
2/21/19 - Attorney General Becerra, Assemblymember Wood Announce Bill to Outlaw Collusive Agreements Between Drug Companies That Inflate Drug Prices
California Attorney General Xavier Becerra issued the following news release:. California Attorney General Xavier Becerra and Assemblymember Jim Wood today unveiled legislation to help curb increasing drug prices in California. These agreements, known as "pay-for-delay" agreements, have significantly contributed to price increases for prescription.
2/21/19 - Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that the company will release its operating and financial results for the transition period from October 1, 2018 to December 31, 2018 before the opening of U.S. markets on Monday,
2/21/19 - AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial
NEW YORK- AzurRx BioPharma, Inc., a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today provided a clinical development and strategic corporate update. Key highlights of OPTION include: Primary endpoint is a six-week non-inferiority, coefficient of fat absorption assessment comparing..
2/21/19 - AzurRx BioPharma Inc (NASDAQ:AZRX) had its Buy rating reiterated by HC Wainwright with a $8.00 price target
Analyst Ratings For AzurRx BioPharma Inc (NASDAQ:AZRX) Today, HC Wainwright reiterated its Buy rating on AzurRx BioPharma Inc (NASDAQ:AZRX) with a price target of $8.00. There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock. The current consensus rating on AzurRx BioPharma Inc (NASDAQ:AZRX) is Buy with [?]
2/21/19 - Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen
First commercial program under Bavarian Nordic and Janssen Vaccines& Prevention B.V. collaboration advancing into clinical trials A therapeutic vaccine may represent a novel approach for early treatment and interception of HPV-induced cancers. COPENHAGEN, Denmark, February 21, 2019- Bavarian Nordic A/S today announced that the first patient has bee
2/21/19 - BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan
-BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today presented its 2018 achievements and corporate priorities for 2019. "The positive Phase 1 data reinforces our position that our lead drug candidate BLU-5937 has the potential to be a best-in-class therapeu
2/21/19 - BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
BioDelivery Sciences International, Inc., a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its fourth quarter and full year 2018 financial results after the close of the U.S. financial markets on Thursday, March 14, 2019. About BioDelivery Scien
2/21/19 - Biohaven Enrolls First Patient in Phase 3 Generalized Anxiety Disorder Trial of Troriluzole
NEW HAVEN- Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neuropsychiatric diseases, today announced that it has enrolled its first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415